Sagar Raj Shakya

USPTO Granted Patents = 15 (Patent Applications = 5)

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 8.5

ph-index = 7

Forward Citations = 62(Granted Patents)

Location History:

Longmont, CO (US) (2012)
San Diego, CO (US) (2011 - 2015)
Boulder, CO (US) (2016 - 2019)
San Diego, CA (US) (2013 - 2024)

Company Filing History:

Arena Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12378198 - Crystalline l-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in SIPI receptor-associated disorders (2025-08-05),

2. 11884626 - Crystalline L-arginine salt of ()-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1Preceptor-associated disorders (2024-01-30),

3. 11091435 - Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1Preceptor-associated disorders (2021-08-17),

4. 10676435 - Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound 1) for use in SIPI receptor-associated disorders (2020-06-09),

5. 10329288 - Process for preparing a compound (2019-06-25),

6. 10301262 - Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders (2019-05-28),

7. 9790190 - Process for making hydroxylated cyclopentylpyrimidine compounds (2017-10-17),

8. 9676730 - Process for making hydroxylated cyclopentylpyrimidine compounds (2017-06-13),

9. 9416110 - Process for making hydroxylated cyclopentylpyrimidine compounds (2016-08-16),

10. 9309204 - Process for making hydroxylated cyclopentylpyrimidine compounds (2016-04-12),

11. 9024040 - Processes for preparing benzimidazole compounds (2015-05-05),

12. 8501956 - Benzimidazole compounds (2013-08-06),

13. 8383832 - Process for preparing benzimidazole compounds (2013-02-26),

14. 8183385 - SNAR process for preparing benzimidazole compounds (2012-05-22),

15. 8039637 - Process for preparing benzimidazole compounds (2011-10-18),

Title: The Innovative Work of Inventor Sagar Raj Shakya

Introduction: Sagar Raj Shakya, a prolific inventor based in San Diego, CA, has made significant contributions to the field of pharmaceuticals with a total of 14 patents to his name. His cutting-edge research has focused on developing novel treatments for S1P receptor-associated disorders, demonstrating his commitment to advancing medical science.

Latest Patents: One of Shakya's latest patents involves a crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound1). This invention showcases a unique crystalline free-plate habit or morphology, along with innovative processes for its preparation. The compound shows promising potential in treating a range of S1P receptor-associated disorders, including autoimmune diseases, cancer, inflammatory conditions, and vascular integrity defects.

Career Highlights: Throughout his career, Shakya has been associated with renowned companies in the pharmaceutical industry. He has lent his expertise to Array Biopharma Inc. and Genentech, Inc., where he has played a pivotal role in driving research and development initiatives. His patents stand as a testament to his dedication to innovation and his ability to push the boundaries of scientific discovery.

Collaborations: Shakya's collaborations with esteemed professionals in the field have further enriched his inventive endeavors. Notable coworkers like Keith Lee Spencer and Peter J Stengel have contributed to the success of his projects, highlighting Shakya's collaborative spirit and his ability to thrive in a team-oriented environment.

Conclusion: Sagar Raj Shakya's trailblazing work in the realm of pharmaceutical innovations underscores his status as a visionary inventor. With a keen focus on addressing unmet medical needs and enhancing treatment options for complex disorders, Shakya stands at the forefront of pioneering research. His patents not only showcase his technical prowess but also reflect his unwavering commitment to improving global healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.